Screening for bladder cancer in people with Lynch syndrome using urine tests

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on individuals diagnosed with Lynch syndrome, a hereditary condition that increases the risk of various cancers, particularly urothelial carcinoma. The study aims to utilize a urine tumor DNA panel to detect asymptomatic urothelial cancers in this high-risk population, comparing its effectiveness against traditional urine cytology methods. By identifying cancers early, the trial seeks to improve outcomes for patients with Lynch syndrome, who have a significant lifetime risk of developing urothelial cancer. Participants will be recruited from specific locations, including Tampere University Hospital and the Vancouver Prostate Centre.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing and able to provide informed consent
* Diagnosis of Lynch syndrome
* Age 50 - 75 years at study recruitment

Exclusion Criteria:

* Concurrent urothelial carcinoma

Where it's running

• Vancouver Prostate Centre
  Vancouver, Canada Recruiting
• Tampere University Hospital and Tampere University
  Tampere, Finland Recruiting

Study contacts

• Principal investigator: Jussi Nikkola, MD, PhD — Tampere University Hospital
• Study coordinator: Jussi Nikkola, MD, PhD
• Email: jussi.nikkola@fimnet.fi
• Phone: 03311611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urothelial Carcinoma Biospecimen Collection and Data Study

  This project tests collecting and storing tissue, blood, and imaging data from adults with urothelial carcinoma to support translational research.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07789119

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• BMS-986504 combined with standard treatments for certain metastatic MTAP‑deleted solid tumors

  This trial tests whether adding the experimental drug BMS‑986504 to standard cancer treatments is safe for people with advanced MTAP‑deleted mesothelioma, gastroesophageal, or urothelial cancers.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07532902

• Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy

  This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07506057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.